Ahola-Olli AV, Wurtz P, Havulinna AS et al (2017) Genome-wide association study identifies 27 loci influencing concentrations of circulating cytokines and growth factors. Am J Hum Genet 100(1):40–50. https://doi.org/10.1016/j.ajhg.2016.11.007

Article  PubMed  CAS  Google Scholar 

Balabanian K, Couderc J, Bouchet-Delbos L et al (2003) Role of the chemokine stromal cell-derived factor 1 in autoantibody production and nephritis in murine lupus. J Immunol 170(6):3392–3400. https://doi.org/10.4049/jimmunol.170.6.3392

Article  PubMed  CAS  Google Scholar 

Bauer JW, Baechler EC, Petri M et al (2006) Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med 3(12):e491. https://doi.org/10.1371/journal.pmed.0030491

Article  PubMed  CAS  Google Scholar 

Bentham J, Morris DL, Graham DSC et al (2015) Genetic association analyses implicate aberrant regulation of innate and adaptive immunity genes in the pathogenesis of systemic lupus erythematosus. Nat Genet 47(12):1457–1464. https://doi.org/10.1038/ng.3434

Article  PubMed  CAS  Google Scholar 

Burgess S, Butterworth A, Thompson SG (2013) Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol 37(7):658–665. https://doi.org/10.1002/gepi.21758

Article  PubMed  Google Scholar 

Calvani N, Richards HB, Tucci M et al (2004) Up-regulation of IL-18 and predominance of a Th1 immune response is a hallmark of lupus nephritis. Clin Exp Immunol 138(1):171–178. https://doi.org/10.1111/j.1365-2249.2004.02588.x

Article  PubMed  CAS  Google Scholar 

Capuano A, Costanzi S, Peluso G et al (2006) Hepatocyte growth factor and transforming growth factor beta1 ratio at baseline can predict early response to cyclophosphamide in systemic lupus erythematosus nephritis. Arthritis Rheum 54(11):3633–3639. https://doi.org/10.1002/art.22192

Article  PubMed  CAS  Google Scholar 

Carter EE, Barr SG, Clarke AE (2016) The global burden of SLE: prevalence, health disparities and socioeconomic impact. Nat Rev Rheumatol 12(10):605–620. https://doi.org/10.1038/nrrheum.2016.137

Article  PubMed  Google Scholar 

Ding T, Yi T, Li Y et al (2023) Luteolin attenuates lupus nephritis by regulating macrophage oxidative stress via HIF-1α pathway. Eur J Pharmacol 953:175823. https://doi.org/10.1016/j.ejphar.2023.175823

Article  PubMed  CAS  Google Scholar 

Esfandiari E, McInnes IB, Lindop G et al (2001) A proinflammatory role of IL-18 in the development of spontaneous autoimmune disease. J Immunol 167(9):5338–5347. https://doi.org/10.4049/jimmunol.167.9.5338

Article  PubMed  CAS  Google Scholar 

Favilli F, Anzilotti C, Martinelli L et al (2009) IL-18 activity in systemic lupus erythematosus. Ann N Y Acad Sci 1173:301–309. https://doi.org/10.1111/j.1749-6632.2009.04742.x

Article  PubMed  CAS  Google Scholar 

Furuse S, Fujii H, Kaburagi Y et al (2003) Serum concentrations of the CXC chemokines interleukin 8 and growth-regulated oncogene-alpha are elevated in patients with systemic sclerosis. J Rheumatol 30(7):1524–1528

PubMed  CAS  Google Scholar 

Geneva-Popova MG, Popova-Belova SD, Gardzheva PN et al (2022) A study of IFN-alpha-induced chemokines CCL2, GRO-A0 and CCL19 in patients with systemic lupus erythematosu. Life (Basel) 12 (2). https://doi.org/10.3390/life12020251

Ghafouri-Fard S, Shahir M, Taheri M et al (2021) A review on the role of chemokines in the pathogenesis of systemic lupus erythematosus. Cytokine 146:155640. https://doi.org/10.1016/j.cyto.2021.155640

Article  PubMed  CAS  Google Scholar 

Hanaoka H, Okazaki Y, Hashiguchi A et al (2015) Overexpression of CXCR4 on circulating B cells in patients with active systemic lupus erythematosus. Clin Exp Rheumatol 33(6):863–870

PubMed  CAS  Google Scholar 

Haringman JJ, Gerlag DM, Smeets TJ et al (2006) A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum 54(8):2387–2392. https://doi.org/10.1002/art.21975

Article  PubMed  CAS  Google Scholar 

Hayakawa I, Hasegawa M, Matsushita T et al (2005) Increased cutaneous T-cell-attracting chemokine levels in sera from patients with systemic sclerosis. Rheumatology (oxford) 44(7):873–878. https://doi.org/10.1093/rheumatology/keh625

Article  PubMed  CAS  Google Scholar 

He J, Sun M, Tian S (2018) Procyanidin B2 prevents lupus nephritis development in mice by inhibiting NLRP3 inflammasome activation. Innate Immun 24(5):307–315. https://doi.org/10.1177/1753425918780985

Article  PubMed  CAS  Google Scholar 

Homey B, Alenius H, Muller A et al (2002) CCL27-CCR10 interactions regulate T cell-mediated skin inflammation. Nat Med 8(2):157–165. https://doi.org/10.1038/nm0202-157

Article  PubMed  CAS  Google Scholar 

Idborg H, Eketjall S, Pettersson S et al (2018) TNF-alpha and plasma albumin as biomarkers of disease activity in systemic lupus erythematosus. Lupus Sci Med 5(1):e000260. https://doi.org/10.1136/lupus-2018-000260

Article  PubMed  PubMed Central  Google Scholar 

Inoue A, Hasegawa H, Kohno M et al (2005) Antagonist of fractalkine (CX3CL1) delays the initiation and ameliorates the progression of lupus nephritis in MRL/lpr mice. Arthritis Rheum 52(5):1522–1533. https://doi.org/10.1002/art.21007

Article  PubMed  CAS  Google Scholar 

Jafari-Nakhjavani MR, Abedi-Azar S, Nejati B (2016) Correlation of plasma interleukin-18 concentration and severity of renal involvement and disease activity in systemic lupus erythematosus. J Nephropathol 5(1):28–33. https://doi.org/10.15171/jnp.2016.05

Article  PubMed  Google Scholar 

Jakiela B, Kosalka J, Plutecka H et al (2018) Urinary cytokines and mRNA expression as biomarkers of disease activity in lupus nephritis. Lupus 27(8):1259–1270. https://doi.org/10.1177/0961203318770006

Article  PubMed  CAS  Google Scholar 

Kuo YT, Jan RL, Kuo CH et al (2012) Effects of vitamin D3 on the expression of growth-related oncogene-alpha in THP-1 cells and human primary monocytes. J Food Sci 77(2):H47-52. https://doi.org/10.1111/j.1750-3841.2011.02532.x

Article  PubMed  CAS  Google Scholar 

Lit LC, Wong CK, Tam LS et al (2006) Raised plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus. Ann Rheum Dis 65(2):209–215. https://doi.org/10.1136/ard.2005.038315

Article  PubMed  CAS  Google Scholar 

Lorenzo-Vizcaya A, Isenberg DA (2021) The use of anti-TNF-alpha therapies for patients with systemic lupus erythematosus. Where are we now? Expert Opin Biol Ther 21 (5):639–647. https://doi.org/10.1080/14712598.2021.1853096

Mao YM, Zhao CN, Leng J et al (2019) Interleukin-13: a promising therapeutic target for autoimmune disease. Cytokine Growth Factor Rev 45:9–23. https://doi.org/10.1016/j.cytogfr.2018.12.001

Article  PubMed  CAS  Google Scholar 

Martinez-Micaelo N, Gonzalez-Abuin N, Ardevol A et al (2012) Procyanidins and inflammation: molecular targets and health implications. BioFactors 38(4):257–265. https://doi.org/10.1002/biof.1019

Article  PubMed  CAS  Google Scholar 

Mende R, Vincent FB, Kandane-Rathnayake R et al (2018) Analysis of serum interleukin (IL)-1beta and IL-18 in systemic lupus erythematosus. Front Immunol 9:1250. https://doi.org/10.3389/fimmu.2018.01250

Article  PubMed  CAS  Google Scholar 

Okada Y, Wu D, Trynka G et al (2014) Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 506(7488):376–381. https://doi.org/10.1038/nature12873

Article  PubMed  CAS  Google Schola